European Union - English - EMA (European Medicines Agency)

novo nordisk a/s - nonacog beta pegol - hemophilia b - antihemorrhagics - treatment and prophylaxis of bleeding in patients with haemophilia b (congenital factor ix deficiency)., refixia can be used for all age groups.,

Israel - English - Ministry of Health

novo nordisk ltd., israel - nonacog beta pegol - powder and solvent for solution for injection - nonacog beta pegol 1000 iu/vial - coagulation factor ix - treatment and prophylaxis of bleeding in pretreated patients with haemophilia b (congenital factor ix deficiency).

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - nonacog beta pegol, quantity: 500 iu/ml - injection, solvent for - excipient ingredients: sodium hydroxide; hydrochloric acid; histidine; water for injections - treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia b (congenital factor ix deficiency).

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - nonacog beta pegol, quantity: 250 iu/ml - injection, solvent for - excipient ingredients: hydrochloric acid; sodium hydroxide; histidine; water for injections - treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia b (congenital factor ix deficiency).

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - nonacog beta pegol, quantity: 125 iu/ml - injection, solvent for - excipient ingredients: histidine; water for injections; sodium hydroxide; hydrochloric acid - treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia b (congenital factor ix deficiency).

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - eftrenonacog alfa, quantity: 250 iu - drug delivery system - excipient ingredients: - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - eftrenonacog alfa, quantity: 3000 iu - drug delivery system - excipient ingredients: - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - eftrenonacog alfa, quantity: 2000 iu - drug delivery system - excipient ingredients: - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - eftrenonacog alfa, quantity: 1000 iu - drug delivery system - excipient ingredients: - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - eftrenonacog alfa, quantity: 500 iu - drug delivery system - excipient ingredients: - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)